New perspectives for the treatment of endometriosis
|
|
- Roland Payne
- 5 years ago
- Views:
Transcription
1 Archives of Perinatal Medicine 18(1), 22-26, 2012 REVIEW PAPER New perspectives for the treatment of endometriosis STEFANO LUISI, VALENTINA CIANI, SERENA PINZAUTI, CLAUDIA TOSTI, LUCIA LAZZERI, SANDRO RAZZI, ERRICO ZUPI, FELICE PETRAGLIA Abstract Endometriosis is a chronic condition characterized by growth of endometrial tissue outside the utero. Common symptoms include dysmenorrhoea, dyspareunia, non-cyclic pelvic pain, and infertility. Endometriosis is often treated surgically upon diagnosis but with a higher rate of recurrence, suggesting that a combination of surgical and medical management might provide better outcomes. The primary goal of medical treatment is to interrupt the growth and activity of endometriosis lesions. Due to the chronic nature of this disease, long-term or repeated courses of medication may be required to control symptoms. Increasing knowledge about the pathogenesis of endometriosis at the cellular and molecular levels may give us the opportunity to use new, specific agents for treatment, including aromatase inhibitors, and new pharmaceutical agents affecting inflammation, oxidative stress, proliferation, angiogenesis and apoptosis. Many of these promising new agents may prevent or inhibit the development of endometriosis. Key words: endometriosis, aromatase inhibitors, thiazolidinediones, omega-3, antiangiogenetic agents Introduction Endometriosis is a chronic condition characterized by growth of endometrial tissue in sites other than the uterine cavity, most commonly in the pelvic cavity, including the ovaries, the uterosacral ligaments, and pouch of Douglas. Common symptoms include dysmenorrhoea, dyspareunia, non-cyclic pelvic pain, and infertility. The etiology is not known and is probably multifactorial, there are a number of theories on how endometrial tissue occurs outside the uterus, including retrograde menstruation through the fallopian tubes, transportation of tissue in the blood or lymph, and the local differentiation of mesothelial or blood cells into endometrium-like tissue [1]. For long time, the treatment of endometriosis has been based primarily on the radical removal of lesions. This is still a mainstay of therapy in cases of bowel and ureteral stenosis or adnexal masses with ultrasonographically doubtful characteristics. In the past two decades, a more pragmatic approach to the treatment of endometriosis has developed, centered more on the woman s needs than on the extension of lesions. In other words, the problems of patients with endometriosis are disease-related symptoms and not implants per se, and treatments should be focused on resolution of complaints, independently of a priori excision of lesions. Current medical management of endometriosis is based on combined oral contraceptives, antinflam-- matory drugs, danazol, gonadotropin-releasing hormone (GnRH) analogues, progestins and steroids receptor modulators have been extensively used in clinical practice. Novel agents, that will hopefully improve the therapeutic potential, include aromatase inhibitors, immunomodulators, anti-inflammatory, antiangiogenetic and antiproliferative agents [2]. Aromatase inhibitors The aromatase enzyme catalyzes a terminal steroidogenesis step that leads to estrogen synthesis, by converting androgens into estrogens in a unidirectional pathway. Estrogen produced in extragonadal tissue acts locally at these sites as paracrine or even intracrine factors [3]. These sites include the mesenchymal cells of adipose tissue, breast, osteoblasts and chondrocytes of bone, the vascular endothelium and aortic smooth muscle cells, and numerous sites in the brain. The control of local estrogen production is modulated through the changes of aromatase. A non gonadal source of estrogen can sometimes contributes significantly to the circulating pool of estrogen, e.g. adipose tissue estrogen contribution. Sufficient circulating levels of the biologically active estrogen, estradiol, can be produced as a result of extraglandulr aromatization of androstenedione to estrone that is subsequently reduced to estradiol in peripheral tissues. Such biologically active estradiol can activate several estrogendependant reproductive disorders including endometriosis, abnormal uterine bleeding, endometrial hyperplasia Department of Pediatrics, Obstetrics and Reproductive Medicine, University of Siena, Siena, Italy
2 New perspectives for the treatment of endometriosis 23 and cancer. Blocking estrogen production by inhibiting the enzyme catalyzing the main step of its synthesis from androgens (aromatase enzyme) is an exciting treatment modality for estrogen-dependant disorders. The third generation of aromatase inhibitors effectively block estrogen synthesis without exerting effects on other steroidogenic pathways and have been heralded as a triumph in translational oncology. They are highly selective and do not affect glucocorticoids, mineralcorticoids, or thyroxine secretion [4]. Significant levels of aromatase enzyme activity and expression have been detected in the stromal cell component of endometriosis. In addition, the eutopic endometrium of women with endometriosis has been found to contain low but significant levels of aromatase enzyme activity and expression [5]. The use of aromatase inhibitors for medical management of endometriosis is still experimental, two pilot studies examined pain relief after 6 months of daily treatment with an aromatase inhibitor together with high-dose norethindrone acetate or an oral contraceptive. Both showed significant (but not complete) resolution of pelvic pain in women with endometriosis who had not responded to first-line treatment. Since the women were premenopausal, the progestin or combined oral contraceptive was added to the aromatase inhibitor bone mass density was stable over the 6 months of the study. Further research is required to determine if aromatase inhibitors will be safe and effective for long-term use in women with endometriosis pain. Aromatase inhibitors are also believed to have the following roles in endometriosis-associated infertility: suppressing endometriotic lesions and ovarian stimulation agents [6]. In general third generation aromatase inhibitors have been found very well tolerated with few significant side effects and a low rate of discontinuation due to adverse reactions. Most common side effects reported are: headaches, gastrointestinal symptoms, arthralgia and problems related to estrogen deprivation [7]. Antiangiogenic agents Angiogenesis is an important component of the pathogenesis of endometriosis. Establishment of blood supply through angiogenesis seems to be a second basic step in the development of the disease after implantation of endometrial fragments in the peritoneal cavity [8]. The endometrium of women with endometriosis has an increased capacity to proliferate, implant and grow in the peritoneal cavity. Different antiangiogenetic treatments such as anti-vegf agents and other angiostatic drugs have been tested in experimental models of endometriosis with successful results inhibiting new vessels formation [9]. These drugs, mainly with cytotoxic properties, target specifically the endothelial cells without penetrate in the tissues. Angiostatic therapy can affect to various angiogenic response stages blocking: endothelial cell proliferation (TNP-470), endothelium-specific integrin survival signaling (vitaxin), extracellular matrix breakdown (batimastat) [10]. The vasculature is a promising target because of its genetic stability, easy access via the circulation and amplifying action during treatment [11]. Another major challenge of vascular therapy in endometriosis is developing more efficient drugs to target pericyte-coated vessels found in more advanced pelvic endometriotic lesions, as well as ovarian and rectovaginal endometriosis [12]. A part from the antiangiogenic substances, it has been shown that other products are effective in the VEGF system regulation. Interestingly, the severity of endometriosis has been directly correlated with spontaneous hyperprolactinemia or after stimulation with different agents. Prolactin (PRL) is a powerful angiogenic inductor and experimentally it induces angiogenesis in tissue like muscle [13]. The dopamine neurotransmitter, used in nontoxic levels, is able to promote the VEGFR-2 endocitosis in endothelial cells, blocking a critical step in the neoangiogenesis process. Similarly, dopamine agonists (as bromocriptin) extensively used in gynecology even during pregnancy, exert the same action. Moreover, if the relationship between neoangiogenesis and PRL is considered together with the relationship between PRL and endometriosis, and the expression of VEGF in ectopic endometrium, dopamine agonists are obvious candidates for the treatment of endometriosis [14]. Anti-inflammatory and antioxidants agents There is substantial evidence that the pathogenesis of this condition involves increased concentrations of activated macrophages and changes in the cytokine network including interleukin-8 (IL-8), tumor necrosis factor α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), transforming growth factors β (TGF-β) and several other proinflammatory chemoattractant cytokines (IL-1, IL-4, IL-5, IL-6, IL-10, IL-13, IL-15, INF γ ) [15]. Systemic inflammation may be induced by oxidative stress, another important component of endometriosis (Fig. 1) [16]. Leukocytes attracted to an activated by the above mentioned chemokines are a major source of oxidative stress. Furthermore, it appears that endometriosis is associated with depletion of antioxidant capacity. Intraperitoneal levels of vitamin E are decreased, likely due to consum-
3 24 S. Luisi, V. Ciani, S. Pinzauti, C. et al. ption by oxidant reactions. Another important consideration relates to the association of endometriosis with impaired immune recognition and clearance of ectopic endometrial cells, suppressed cytotoxicity of natural killer (NK) cells, as well as activation of B-cells accompanied by increased production of the antinuclear antibodies. Activation of the NF-kB pathway and disturbance of other anti-inflammatory mechanism lead to an overall inflammatory/angiogenic response with upregulation of several cytokines, MCP-1, VEGF, that are controlled by NF-kB [17]. cells, and modulate angiogenesis. PGE2 pg/ml TNF-" +DHA 30 : M +EPA 45 : M Control 0,5 2 5 Proinflammatory cytochines Antinflammatory chemochines Lack of antioxidant 2500 TNF- " ng/ml Excess of reactive oxygen species Chronic inflammatio and endometriosis IL-8 pg/ml TNF-" +EPA 45 : M Fig. 1. Oxidative stress and antioxidant 500 +DHA 30 : M A relationship between dietary fatty acids, dysmenorrhea and endometriosis has been recently suggested [18]. The most common are the n-3 fatty acids, a family of unsatured fatty acids, including eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), which share a common final carbon-carbon double bond in the n-3 position. Omega-3 polyunsaturated fatty acids have a role in the inflammatory process and a therapeutic effect has been suggested and the effect of two omega-3 fatty acids (DHA and EPA), on i) TNF-α induced IL-8 and PGE2 release and on ii) cyclooxygenase-2 (Cox-2) mrna expression, key enzyme for prostaglandin production were evaluated in human cultured endometrial stromal cells. The results show that DHA or EPA significantly reduced the lipopolysaccharide induced IL-8, and PGE2, release decreasing the expression of Cox-2, underlying an inhibitory effect of omega-3 fatty acids on inflammatory mediators secretion, suggests a potential benefit in treatment of pelvic pain in patients with endometriosis (Fig. 2) [19]. The thiazolidinediones (TZDs), are a class of medications used in the treatment of diabetes mellitus type 2, introduced in the late 1990s. TZDs and have been shown to inhibit both monocyte migration and peritoneal inflammatory cells in a mouse model, decrease chemokine and cytokine expression in endometriotic stromal 0 rosiglitazone + Control 0,5 2 5 Fig. 2. Inflammation and endometriosis: rationale for using omega-3 PAR-( LXR-" Anti-inflammatory effect _ COX 2 IL-1 pioglitazone _ VEGF Anti-angiogenic effect Fig. 3. Inflammation and endometriosis: rationale for using thiazolidinediones Both rodent and baboon models of endometriosis have been utilized to demonstrate decreased endometriotic lesion burden with TZDs as compared with placebo. No human trial currently exists in the literature except preliminary recent data collected by limited series of patients (n = 6) with endometriosis treated with rosiglitazone for 6 months. While rosiglitazone has been given a black box
4 New perspectives for the treatment of endometriosis 25 warning label from the FDA due to an increased risk of cardiovascular side effects in heart failure patients, pioglitazone remains on the market and might be a viable substitute. Since we are suggesting the possibility of using TZDs for endometriosis pain relief in conjunction with attempts to conceive, it must be understood that, under the current FDA safety classification scheme, TZDs are listed as a class C drug (Fig. 3) [20]. Antiproliferative and proapoptosis agents Statins may be effective in the treatment of endometriosis, targeting growth and invasiveness of ectopic endometrial tissues as well as inflammation and oxidative stress associated with this condition [21]. Formation of endometriotic implants requires ectopic attachment and proliferation of endometrial stroma and glands. The rationale for considering statins as a promising treatment of endometriosis is based on several considerations: statins are competitive inhibitors of 3-hydroxy-3- methylglutaryl-coenzime A (HMG-CoA) reductase, a ratelimiting step of the mevalonate pathway, they decrease the mitogenic effect of IGF-I on endometrial stromal cells, moreover statins can interfere with angiogenesis (Fig. 4) [22]. Statins Cel proliferation Angiogenesis Inflammation, oxidative stress Endometriosis Fig. 4. Proposed role of statins in treatment of endometriosis In addition statins possess anti-inflammatory and immune-modulatory properties, which may reduce the inflammatory reaction associated with endometriosis. Another and related aspect of the action of the statins pertains to their anti-oxidant properties. Proliferation of endometrial stroma is stimulated by moderate oxidative stress, but inhibited by a broad range of antioxidant [23]. A recent study demonstrates that in cultures of human endometrial stroma: 1) simvastatin induces a wave of apoptosis and profound morphological changes including cell shrinkage and derangement of the cytoskeleton; and 2) these effects of simvastatin are abrogated in the presence of geranyl pyrophosphate (GGPP). The regulation of apoptotic death of endometrial stromal cells is likely to be an important mechanism controlling the growth of endometrial tissues [24]. Conclusions Endometriosis remains a prevalent condition in women of reproductive age, characterized by the presence of endometrial tissue in extra-uterine sites, including the ovaries and other pelvic structures. In the absence of definitive cure, the management of endometriosis must be set within the framework of long-term therapeutic strategies. The medical treatment of endometriosis in the next future will be enriched by several possible strategies. Hormonal and antinflammatory drugs will be available in new formulations and their possible combination will be evaluated in order to defeat endometriosis. Author Disclosure Statement: No competing financial interests exist. References [1] Bulun S.E. (2009) Endometriosis. N. Engl. J. Med. 360: [2] Practice Commitee of the American Society for Reproductive Medicine. (2008) Treatment of pelvic pain associated with endometriosis. Fertil. Steril. 3: [3] Simpson E.R. (2003) Sources of estrogen and their importance. J. Steroid. Biochem. Mol. Biol. 86: [4] Bhatnagar A.S. (2007) The discovery and mechanism of action of letrozole. Breast. Cancer. Res. Treat. 105: [5] Noble L.S., Takayama K., Zeitoun K.M. et al. (1997) Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J. Clin. Endocrinol. Metab. 82: [6] Lossl K., Loft A., Freiesleben N.L. et al. (2009) Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-a pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 144: [7] Amsterdam L.L., Gentry W., Jobanputra S. et al. (2005) Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil. Steril. 84: [8] Maas J.W., Groothuis P.G., Dunselman G.A et al. (2001) Endometrial angiogenesis throughout the human menstrual cycle. Hum. Reprod. 16: [9] Becker C.M., Wright R.D., Satchi-Fainaro R. et al. (2006) A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am. J. Pathol. 168: [10] McCarty M.F., Liu W., Fan F. et al. (2003) Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends. Mol. Med. 9: [11] Girling J.E., Rogers P.A. (2005) Recent advances in endometrial angiogenesis research. Angiogenesis 8: [12] Kressin P., Wolber E.M., Wodrich H. et al. (2001) Vascular endothelial growth factor mrna in eutopic and ectopic endometrium. Fertil. Steril. 76: [13] Ko J.Y., Ahn Y.L., Cho B.N. (2003) Angiogenesis and white blood cell proliferation induced in mice by injection of a prolactin-expressing plasmid into muscle. Mol. Cells. 15:
5 26 S. Luisi, V. Ciani, S. Pinzauti, C. et al. [14] Nap A.W., Griffioen A.W., Dunselman G.A. et al. (2004) Antiangiogenesis therapy for endometriosis. J. Clin. Endocrinol. Metab. 89: [15] Arici A. (2002) Local cytokines in endometrial tissue: the role of interleukin-8 in the pathogenesis of endometriosis. Ann. N. Y. Acad. Sci. 955: [16] Jackson L.W., Schisterman E.F., Dey-Rao R. et al. (2005) Oxidative stress and endometriosis. Hum. Reprod. 20: [17] Siristatidis C., Nissotakis C., Chrelias C. et al. (2006) Immunological factors and their role in the genesis and development of endometriosis. J. Obstet. Gynaecol. Res. 32: [18] Goldberg R.J, Katz J. (2007) A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain 129: [19] Novembri R., Luisi S., Carrarelli P. et al. (2011) Omega 3 fatty acids counteract IL-8 and prostaglandin E2 secretion induced by TNF-α in cultured endometrial stromal cells. Journal of Endometriosis 3: [20] Moravek M.B., Ward E.A., Lebovic D.I. (2009) Thiazolidinediones as therapy for endometriosis: a case series. Gynecol. Obstet. Invest. 68: [21] Wassmann S., Laufs U., Müller K. et al. (2002) Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 22: [22] Skaletz-Rorowski A., Walsh K. (2003) Statin therapy and angiogenesis. Curr. Opin. Lipidol. 14: [23] Foyouzi N., Berkkanoglu M., Arici A. et al. (2004) Effects of oxidants and antioxidants on proliferation of endometrial stromal cells. Fertil. Steril. 82: [24] Laschke M.W., Elitzsch A., Scheuer C. et al. (2007) Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis. Fertil. Steril. 87: J Stefano Luisi Department of Pediatrics, Obstetrics and Reproductive Medicine University of Siena, Policlinico Le Scotte Viale Bracci Siena, Italy stefano.luisi@unisi.it
Medical Management of Endometriosis: Novel Targets and Future Treatments Erkut Attar, M.D. PhD.
Medical Management of Endometriosis: Novel Targets and Future Treatments Erkut Attar, M.D. PhD. Istanbul University Istanbul Medical School Department of Obstetrics & Gynecology Division of Reproductive
More informationEndometrio ed endometriosi: the same tissue?
Endometrio ed endometriosi: the same tissue? Valentino Remorgida Clinica Ostetrica e Ginecologica IRCCS Azienda Ospedaliera Universitaria San Martino IST Istituto Nazionale per la Ricerca sul Cancro, Università
More informationStem cells in endometriosis: pathogenetic factors and target for new medical treatments? Alberto Revelli MD PhD
Stem cells in endometriosis: pathogenetic factors and target for new medical treatments? Alberto Revelli MD PhD Gyn/Obst 1U, Physiopathology of Reproduction and IVF Unit Dept. Surgical Sciences, S. Anna
More informationENDOMETRIOSIS When and how to implement treatment
ENDOMETRIOSIS When and how to implement treatment Francisco Carmona Hospital Clínic ENDOMETRIOSIS TREATMENT It depends on the severity of symptoms the patient's desire for pregnancy the extent of disease
More informationMANAGEMENT OF REFRACTORY ENDOMETRIOSIS
(339) MANAGEMENT OF REFRACTORY ENDOMETRIOSIS Serdar Bulun, MD JJ Sciarra Professor and Chair Department of Ob/Gyn Northwestern University ENDOMETRIOSIS OCs Teenager: severe dysmenorrhea often starting
More informationEndometriosis and oxidative stress?
Endometriosis and oxidative stress? Pietro Santulli MD, PhD Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, AP-HP, Cochin Saint Vincent de Paul, Department of Gynecology Obstetrics
More informationReview Article Pathophysiology and Immune Dysfunction in Endometriosis
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 795976, 12 pages http://dx.doi.org/10.1155/2015/795976 Review Article Pathophysiology and Immune Dysfunction in Endometriosis
More information: 0 0: 770 years yeas of history stoy
Siena, Piazza del Campo 1240-2010: 0 0: 770 years yeas of history stoy Siena, Policlinico Universitario Santa Maria alle Scotte Endometriosis: symptoms Infertility Pain Endometriosis and infertility: possible
More informationSAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:
Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex
More informationResults of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A.
Results of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A. Ott's Research Institute of Obstetrics, Gynecology and Reproductology,
More informationORILISSA (elagolix) oral tablet
ORILISSA (elagolix) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationDefinition Endometriosis is the presence of functioning endometrial tissue outside the cavity of the uterus.
Dept. of Obstetrics t and Gynecology Faculty of Medicine University of Sumatera Utara Endometriosis Definition Endometriosis is the presence of functioning endometrial tissue outside the cavity of the
More informationPalm Beach Obstetrics & Gynecology, PA
Palm Beach Obstetrics & Gynecology, PA 4671 S. Congress Avenue, Lake Worth, FL 33461 561.434.0111 4631 N. Congress Avenue, Suite 102, West Palm Beach, FL 33407 Endometriosis The lining of the uterus is
More informationEndometriosis. What you need to know. 139 Dumaresq Street Campbelltown Phone Fax
Endometriosis What you need to know 139 Dumaresq Street Campbelltown Phone 4628 5292 Fax 4628 0349 www.nureva.com.au September 2015 What is Endometriosis? Endometriosis is a condition whereby the lining
More informationWHAT IS ENDOMETRIOSIS?
WHAT IS ENDOMETRIOSIS? Endometriosis is a common and sometimes debilitating condition affecting 7-10% of women of any nationality and has no cure. It is an estrogen dependent disease, so affects women
More informationDifference Between PCOS and Endometriosis
Difference Between PCOS and Endometriosis www.differencebetween.com Key Difference PCOS vs Endometriosis Ovaries play an important role in the reproduction and the maintenance of the female body. They
More information(BMI)=18.0~24.9 kg/m 2 ;
33 10 Vol.33 No.10 2013 10 Oct. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.10.0672 E-mail: randc_journal@163.com - ( 400013) : () GnRH-a - () : IVF- ET 233 A (I~II 102 ) B (III~IV
More informationEndometriosis د. نجمه محمود كلية الطب جامعة بغداد فرع النسائية والتوليد
Endometriosis د. نجمه محمود كلية الطب جامعة بغداد فرع النسائية والتوليد Objectives:- To know what is endometriosis The sites where it occur To explain its itiology & pathogenesis To know the clinical features
More informationCASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?
CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,
More informationUterine Fibroids: No financial disclosures. Current Challenges, Promising Future. Off-label uses of drugs. Alison Jacoby, MD.
Uterine Fibroids: Current Challenges, Promising Future Alison Jacoby, MD Professor, Dept of Obstetrics, Gynecology and Reproductive Sciences No financial disclosures Off-label uses of drugs The BIG Questions
More informationMenstrual Discomfort L O O K, F E E L A N D L I V E B E T T E R
Menstrual Discomfort LOOK, FEEL AND LIVE BET TER Pycnogenol for Menstrual Discomfort Most women of child-bearing age experience a variety of symptoms related to the menstrual cycle that may be limited
More informationEndometriosis is a complex disease characterized
MINERVA GINECOL 2006;58:527-51 Serum and peritoneal abnormalities in endometriosis: potential use as diagnostic markers S. GUPTA 1, 2, A. AGARWAL 1, 2, L. SEKHON 1, 2, N. KRAJCIR 1, 2, M. COCUZZA 1, 2,
More informationNew Treatment Modalities for Chronic Pelvic Pain
New Treatment Modalities for Chronic Pelvic Pain Definition Chronic pelvic pain is defined as pain that occurs below the umbilicus that lasts for at least six months and is severe enough to cause functional
More informationDysmenorrhoea Gynaecology د.شيماءعبداالميرالجميلي. Aetiology of secondary dysmenorrhea
30-11-2014 Gynaecology Dysmenorrhoea د.شيماءعبداالميرالجميلي Dysmenorrhoea is defined as painful menstruation. It is experienced by 45 95 per cent of women of reproductive age.primary Spasmodic Dysmenorrhea
More informationCancer in Women after Menopause
Cancer in Women after Menopause BELGIAN MENOPAUSE SOCIETY SEPTEMBER 19, 2009 A. Pintiaux ULg Gynaecological Uses of a New Class of Steroids : the Selective Progesterone Receptor Modulators BELGIAN MENOPAUSE
More informationPre and post surgical medical therapy. Mauro Busacca M.D. Dept of Obstetrics and Gynecology University of Milan- Italy
Pre and post surgical medical therapy Mauro Busacca M.D. Dept of Obstetrics and Gynecology University of Milan- Italy introduction A disease is an open problem when two conditions are nor satisfied: The
More informationA multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of
A multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of Endometrioma and deep infiltrating endometriosis Professor C. Chapron and the Group
More informationMoneli Golara Consultant Obstetrician and Gynaecologist Barnet Hospital Royal Free NHS Trust
Moneli Golara Consultant Obstetrician and Gynaecologist Barnet Hospital Royal Free NHS Trust Endometriosis one of the most common conditions requiring treatment Growth of endometrial like tissue outside
More informationArticle Effect of ovarian involvement on peritoneal fluid cytokine concentrations in endometriosis patients
RBMOnline - Vol 14. No 5. 2007 620-625 Reproductive BioMedicine Online; www.rbmonline.com/article/2742 on web 19 March 2007 Article Effect of ovarian involvement on peritoneal fluid cytokine concentrations
More informationEndometriosis Treatment & Management Medscape
Endometriosis Treatment & Management Medscape Updated: Apr 25, 2016 Author: G Willy Davila, MD; Chief Editor: Michel E Rivlin, MD more... Approach Considerations The dependence of endometriosis on the
More informationEndometriosis. *Chocolate cyst in the ovary
Endometriosis What is endometriosis? Endometriosis is a common condition in young women. It's chronic, painful, and it often progressively gets worse over the time. *Chocolate cyst in the ovary Normally,
More informationNEW TREATMENTS FOR OVARIAN ENDOMETRIOMA
SEUD 2018 NEW TREATMENTS FOR OVARIAN ENDOMETRIOMA Ivo Brosens Giuseppe Benagiano Faculty of Medicine, KU Leuven, Belgium Sapienza University, Rome, Italy Hughesdon P.E. (1957) THE OVARIAN ENDOMETRIOMA
More informationSurgical Management of Endometriosis associated Infertility
Surgical Management of Endometriosis associated Infertility Dr. Ingrid Lok Specialist in Obstetrics and Gynaecology (Honorary Clinical Associate Professor, CUHK) HA commission training 24.2.2014 Endometriosis
More informationReview. Endometriosis: a role for stem cells
Endometriosis is a complex gynecologic condition affecting 6 10% of reproductive aged women and is a major cause of chronic pain and infertility. Mechanisms of disease pathogenesis are poorly understood.
More informationReproductive Health and Pituitary Disease
Reproductive Health and Pituitary Disease Janet F. McLaren, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology jmclaren@uabmc.edu Objectives
More informationEstrogens & Antiestrogens
Estrogens & Antiestrogens Menstrual cycle... Changes and hormonal events Natural estrogens: Estadiol >> Estrone > Estriol Ineffective orally Synthesis: From cholesterol ; role of aromatase enzyme in converting
More informationUniversal Embryo Cryopreservation: Frozen versus Fresh Transfer. Zaher Merhi, M.D.
Universal Embryo Cryopreservation: Frozen versus Fresh Transfer Zaher Merhi, M.D. Disclosure: None Fewer complications with IVF 1.5% children in US are born through ART 1.1 million children since 2006
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More informationEndometriosis. Assoc.Prof.Pawin Puapornpong, Faculty of Medicine, Srinakharinwirot University.
Endometriosis Assoc.Prof.Pawin Puapornpong, Faculty of Medicine, Srinakharinwirot University. Endometriosis Definition: Ectopic Endometrial Tissue True Incidence Unknown:? 1-5% Does NOT Discriminate by
More informationEndometriosis and Infertility - FAQs
Published on: 8 Apr 2013 Endometriosis and Infertility - FAQs Introduction The inner lining of the uterus is called the endometrium and it responds to changes that take place during a woman's monthly menstrual
More informationSPRMs, androgens and breast cancer
SPRMs, androgens and breast cancer Dr Joëlle Desreux BMS 04/06/2016 WHI : the nuclear explosion Looking for the perfect menopause treatment Hot flushes relieve Osteoporosis prevention Cardio-vascular health
More informationNUTRI ENDO 1 & 2. A scientific breakthrough for Endometriosis
NUTRI ENDO 1 & 2 A scientific breakthrough for Endometriosis ENDOMETRIOSIS Key figures 1 in 10 women of childbearing age... 14 million women in Europe 40 % of women with endometriosis have difficulty conceiving.
More informationEndometriosis an Enigma- Review Article
Volume 2 Issue 1 2018 Page 212 to 217 Editorial Gynaecology and Perinatology ISSN: 2576-8301 Endometriosis an Enigma- Review Article Dr. Sreelatha S 1 *, Dr. Shruthi A 2, Dr. Vandana Ambastha 2, Dr. Asha
More informationRelationship between Energy Expenditure Related Factors and Oxidative Stress in Follicular Fluid
Original Article Relationship between Energy Expenditure Related Factors and Oxidative Stress in Follicular Fluid Abstract This study evaluated the impact of body mass index (BMI), total calorie intake
More informationLaparoscopy and Endometriosis: Preventing Complications and Improving Outcomes. Luis C. Paez M.D.
Laparoscopy and Endometriosis: Preventing Complications and Improving Outcomes Luis C. Paez M.D. Assumptions Pelvic pain Not desiring immediate fertility H & P suggest endometriosis OC/NSAID failures Endo
More informationThe Use of GnRH Agonists in the Treatment of Endometriomas With or Without Drainage
The Use of GnRH Agonists in the Treatment of Endometriomas With or Without Drainage Pages with reference to book, From 30 To 32 Sertac Batioglu, Havva Celikkanat, Mustafa Ugur, Leyla Mollamahmutoglu, Huseyin
More informationSexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist
Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with
More informationSurgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea
Page: 1 of 7 Last Review Status/Date: June 2015 for Primary and Secondary Dysmenorrhea Description Two laparoscopic surgical approaches are proposed as adjuncts to conservative surgical therapy for the
More informationCNGOF Guidelines for the Management of Endometriosis
CNGOF Guidelines for the Management of Endometriosis Anatomoclinical forms of endometriosis Definitions Endometriosis is defined as the presence of endometrial tissue containing both glands and stroma
More informationClinical Case Reports: Open Access
Clinical Case Reports: Open Access Mini Review Vol 1 Iss 2 Surgical Management of Endometriosis- A Mini Review Kanika Chopra *, Debasis Dutta and Kanika Jain Department of Minimally Invasive Gynaecology,
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More informationManagement of Gynae Problems in Primary Care David Griffiths FRCOG The Great Western Hospital Swindon. A brief overview
Management of Gynae Problems in Primary Care David Griffiths FRCOG The Great Western Hospital Swindon A brief overview Pelvic Pain Challenge to the physician In UK 1 Million sufferers 20% of all gynae
More informationSurgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea. Original Policy Date
MP 4.01.10 Surgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea Medical Policy Section OB/Gyn/Reproduction Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationWhat s New in Adolescent Contraception?
What s New in Adolescent Contraception? Abby Furukawa, MD Legacy Medical Group Portland Obstetrics and Gynecology April 29, 2017 Objectives Provide an update on contraception options for the adolescent
More informationMelatonin and its Role in the Inhibition of Breast Cancer Ciara Nicol Ross Copyright 2014 by Ciara Ross and Koni Stone
1 Melatonin and its Role in the Inhibition of Breast Cancer Ciara Nicol Ross Copyright 2014 by Ciara Ross and Koni Stone Cancer is a disease caused by out of control division of abnormal cells within a
More informationEffect of a statin on an in vitro model
ENDOMETRIOSIS Effect of a statin on an in vitro model of endometriosis Navid Esfandiari, D.V.M., Ph.D., Mozafar Khazaei, Ph.D., Jafar Ai, Ph.D., Ryszard Bielecki, D.V.M., Lynda Gotlieb, R.N., Edward Ryan,
More informationTreatment options for primary and secondary dysmenorrhoea
PRESCRIBING IN PRACTICE Treatment options for primary and secondary dysmenorrhoea DIMITRIOS MAVRELOS AND ERTAN SARIDOGAN SPL Dysmenorrhoea affects up to half of young women and can adversely affect quality
More informationCrosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea
Crosstalk between Adiponectin and IGF-IR in breast cancer Prof. Young Jin Suh Department of Surgery The Catholic University of Korea Obesity Chronic, multifactorial disorder Hypertrophy and hyperplasia
More informationFDG-PET value in deep endometriosis
Gynecol Surg (2011) 8:305 309 DOI 10.1007/s10397-010-0652-6 ORIGINAL ARTICLE FDG-PET value in deep endometriosis A. Setubal & S. Maia & C. Lowenthal & Z. Sidiropoulou Received: 3 December 2010 / Accepted:
More informationunderstanding endometriosis Authored by Dr KT Subrayen Sponsored by
understanding endometriosis Authored by Dr KT Subrayen Sponsored by in this booklet What is Endometriosis? 1 What causes Endometriosis? 3 What does Endometriosis look like? 4 Common symptoms of Endometriosis
More informationThe effect of oral contraceptives on aromatase expression in the eutopic endometrium of patients with endometriosis
Gynecological Endocrinology, March 2008; 24(3): 123 128 ENDOMETRIOSIS The effect of oral contraceptives on aromatase expression in the eutopic endometrium of patients with endometriosis HUGO MAIA JR 1,
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationA Rare Presentation of Endometriosis with Recurrent Massive Hemorrhagic Ascites which Can Mislead
Case Report INTERNATIONAL JOURNAL OF WOMEN'S HEALTH AND REPRODUCTION SCIENCES http://www.ijwhr.net A Rare Presentation of Endometriosis with Recurrent Massive Hemorrhagic Ascites which Can Mislead Article
More informationInfertility for the Primary Care Provider
Infertility for the Primary Care Provider David A. Forstein, DO FACOOG Clinical Associate Professor Obstetrics and Gynecology University of South Carolina School of Medicine Greenville Disclosure I have
More informationEndometriosis - MRI findings with anatomic-pathologic correlation
Endometriosis - MRI findings with anatomic-pathologic correlation Poster No.: C-2551 Congress: ECR 2015 Type: Educational Exhibit Authors: E. Matos, A. T. Almeida, A. Sanches; Vila Nova de Gaia/PT Keywords:
More informationInvestigational drugs for the treatment of endometriosis, an update on recent developments
Expert Opinion on Investigational Drugs ISSN: 1354-3784 (Print) 1744-7658 (Online) Journal homepage: http://www.tandfonline.com/loi/ieid20 Investigational drugs for the treatment of endometriosis, an update
More informationPelvic Pain: Overlooked
EDUCATION EXHIBIT 3 Pelvic Pain: Overlooked and Underdiagnosed Gynecologic Conditions 1 CME FEATURE See accompanying test at http:// www.rsna.org /education /rg_cme.html LEARNING OBJECTIVES FOR TEST 1
More informationCLEAR COVERAGE HYSTERECTOMY CHECKLISTS
CLEAR COVERAGE HYSTERECTOMY CHECKLISTS Click on the link below to access the checklist sheet. Abnormal Uterine Bleeding Adenomyosis Chronic Abdominal or Pelvic Pain Endometriosis Fibroids General Guidelines
More informationThe pharmacological management of ENDOMETRIOSIS
The pharmacological management of ENDOMETRIOSIS 18 Endometriosis is a gynaecological condition in which endometrial tissue is present outside the uterine cavity, causing cyclic symptoms and, often, reduced
More informationSurgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea
Surgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea Policy Number: 4.01.17 Last Review: 11/2013 Origination: 11/2007 Next Review: 11/2014 Policy Blue Cross and Blue Shield
More informationA Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis
SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident
More informationIntracrine Androgens Enhance Decidualization and Modulate Expression of Human
Intracrine Androgens Enhance Decidualization and Modulate Expression of Human Endometrial Receptivity Genes. Authors: Douglas A Gibson 1, Ioannis Simitsidellis 1, Fiona L Cousins 1*, Hilary O.D. Critchley
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationEstrogen. Cysteine Prevents oxidation of estrogen into a dangerous form that causes breast cancer. 29,30,31
Cysteine Prevents oxidation of estrogen into a dangerous form that causes breast cancer. 29,30,31 Estrogen lowers risk of zinc de ciency; dependent proteins metabolize estrogen. 26,27,28 Magnesium Cofactor
More informationCY Tse, AMK Chow, SCS Chan. Introduction
Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study CY Tse, AMK Chow, SCS Chan Objective. To evaluate
More informationIVF Protocols: Hyper & Hypo-Responders, Implantation
IVF Protocols: Hyper & Hypo-Responders, Implantation Midwest Reproductive Symposium June 4-5, 4 2010 Subset : Hyper-Responders Mark R. Bush, MD, FACOG, FACS OBJECTIVE: Important goals for the PCOS patient
More informationTheFormationofaScoringSystemtoDiagnoseEndometriosis. The Formation of a Scoring System to Diagnose Endometriosis
Global Journal of Medical Research: E Gynecology and Obstetrics Volume 18 Issue 1 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Online ISSN: 49-4618
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationHormone. Free Androgen Index. 2-Hydroxyestrone. Reference Range. Hormone. Estrone Ratio. Free Androgen Index
Hormonal Health PATIENT: Sample Report TEST REF: TST-12345 Hormonal Health 0.61 0.30-1.13 ng/ml DHEA-S 91 35-430 mcg/dl tient: SAMPLE TIENT e: x: N: Sex Binding Globulin 80 18-114 nmol/l Testosterone 0.34
More informationEndometriosis. A Guide for Patients PATIENT INFORMATION SERIES
Endometriosis A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications Committee.
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date:
Clinical Policy: (Zoladex) Reference Number: ERX.SPA.145 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationCoexistence of Endometriosis and Uterine Dysfunction in Infertile Women
Coexistence of Endometriosis and Uterine Dysfunction in Infertile Women Ludwig Kiesel University of Münster Department of Gynecology and Obstetrics Münster, Germany Symptoms: Risk of Endometriosis Compared
More informationINFERTILITY CAUSES. Basic evaluation of the female
INFERTILITY Infertility is the inability to conceive after 12 months of unprotected intercourse. There are multiple causes of infertility and a systematic way to evaluate the condition. Let s look at some
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal myomectomy in leiomyoma management, 77 Abnormal uterine bleeding (AUB) described, 103 105 normal menstrual bleeding vs., 104
More informationHormonal Control of Human Reproduction
Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with
More informationSTUDY OF BIOLOGICAL MARKERS IN ENDOMETRIOSIS
Analele Științifice ale Universității Alexandru Ioan Cuza, Secțiunea Genetică și Biologie Moleculară TOM XVIII, Fascicula 4, 2017 STUDY OF BIOLOGICAL MARKERS IN ENDOMETRIOSIS EDUARD CRAUCIUC 1, SINDILAR
More informationCHOCOLATE CYST AWARENESS AND LIFESTYLE MODIFICATION A REVIEW
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Sara et al. S JIF Impact Factor 6.041 Volume 5, Issue 9, 1042-1048 Review Article ISSN 2278 4357 CHOCOLATE CYST AWARENESS AND LIFESTYLE MODIFICATION
More informationReviewer #1 (Remarks to the Author)
Reviewer #1 (Remarks to the Author) This manuscript presents an engineering system designed to culture and maintain living tissue from female reproductive organs. The modular capacity, reconfigurability,
More informationEndometriosis Symptoms Often Recur In Teens. (Postsurgery Complaints).(Brief Article): An Article From: Pediatric News [HTML] [Digital] By Kate
Endometriosis Symptoms Often Recur In Teens. (Postsurgery Complaints).(Brief Article): An Article From: Pediatric News [HTML] [Digital] By Kate Johnson If searching for a book Endometriosis symptoms often
More informationThe many faces of Endometriosis
The many faces of Endometriosis Beryl Benacerraf M.D Harvard Medical School What is Endometriosis? Endometriosis is defined as the presence of normal endometrial tissue occurring outside of the endometrial
More informationADENOMYOSIS CHRONIC PELVIC PAIN IN WOMEN IMAGING CHRONIC PELVIC PAIN IN WOMEN CHRONIC PELVIC PAIN IN WOMEN ADENOMYOSIS: PATHOLOGY ADENOMYOSIS
CHRONIC PELVIC PAIN IN WOMEN IMAGING CHRONIC PELVIC PAIN IN WOMEN MOSTAFA ATRI, MD Dipl. Epid. UNIVERSITY OF TORONTO Non-menstrual pain of 6 months Prevalence 15%: 18-50 years of age 10-40% of gynecology
More informationMolecular aspects of development and regulation of endometriosis
Aznaurova et al. Reproductive Biology and Endocrinology 2014, 12:50 REVIEW Open Access Molecular aspects of development and regulation of endometriosis Yana B Aznaurova 1,3,5*, Marat B Zhumataev 1,3,5,
More informationOrilissa (elagolix) NEW PRODUCT SLIDESHOW
Orilissa (elagolix) NEW PRODUCT SLIDESHOW Introduction Brand name: Orilissa Generic name: Elagolix Pharmacological class: GnRH antagonist Strength and Formulation: 150mg, 200mg; tabs Manufacturer: AbbVie
More informationintractable dysmenorrhea are diagnosed with endometriosis. 5
Endometriosis From Identification to Management Endometriosis, a gynecologic disorder that typically affects women of childbearing age, can result in dysmenorrhea, deep dyspareunia, chronic pelvic pain,
More informationManaging infertility when adenomyosis and endometriosis co-exist
Managing infertility when adenomyosis and endometriosis co-exist Jinhua Leng Beijing,China Endometriosis Endometriosis (EM) is a common, benign, ovary hormone-dependent gynecologic disorder which affects
More informationEVALUATION OF MENSTA SYRUP FOR ESTROGENIC ACTIVITY USING FEMALE WISTAR RATS.
EVALUATION OF MENSTA SYRUP FOR ESTROGENIC ACTIVITY USING FEMALE WISTAR RATS. Introduction: The study was conducted to evaluate the effect of Dabur Mensta Syrup in the female reproductive system of experimental
More informationThe menstrual Cycle. François Pralong
The menstrual Cycle François Pralong Services d Endocrinologie, Diabétologie et Métabolisme, Hôpitaux Universitaires de Genève et Lausanne Centre des Maladies CardioVasculaires et Métaboliques, Lausanne
More informationEstrogens and progestogens
Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationEndometriosis is diagnosed by the presence of viable,
Clinical Expert Series Clinical Management of Endometriosis Tommaso Falcone, MD, and Rebecca Flyckt, MD Endometriosis is a common and challenging condition of reproductive-aged women that carries a high
More information